Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial (K-PASS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05233566
Recruitment Status : Recruiting
First Posted : February 10, 2022
Last Update Posted : May 2, 2022
Sponsor:
Information provided by (Responsible Party):
Bradley Fritz, Washington University School of Medicine

Tracking Information
First Submitted Date  ICMJE February 3, 2022
First Posted Date  ICMJE February 10, 2022
Last Update Posted Date May 2, 2022
Actual Study Start Date  ICMJE April 25, 2022
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 3, 2022)
  • Fraction of Approached Patients Who Enroll and Are Randomized [ Time Frame: 3 days after surgery ]
    The numerator will include all patients who are randomized to receive either ketamine or placebo. The denominator will include all patients who are approached by the research to evaluated eligibility and offer consent.
  • Fraction of Randomized Patients Who Complete the Study Infusion [ Time Frame: 3 days after surgery ]
    The numerator will include all participants who receive the study medication for at least 7 of the planned 8 hours. The denominator will include all participants who are randomized to receive either ketamine or the placebo.
  • Fraction of Randomized Patients with Depression Rating Scale Scores at All Specified Time Points [ Time Frame: 14 days after the intervention ]
    Depression will be measured using the Montgomery-Asberg Depression Rating Scale (MADRS) at pre-operative baseline and on post-infusion days 1, 2, 4, 7, and 14. The numerator will include all patients with MADRS scores documented at all 6 time points. The denominator will include all participants who are randomized to receive either ketamine or the placebo.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 3, 2022)
  • Depressive Symptoms on Day 4 [ Time Frame: 4 days after the intervention ]
    Depression will be measured using the Montgomery-Asberg Depression Rating Scale (MADRS) at pre-operative baseline and on post-infusion days 1, 2, 4, 7, and 14. For each randomized participant, the difference in MADRS score on post-infusion day 4 and at the preoperative baseline visit will be calculated. Participants with missing MADRS scores at either time point will be excluded. (No imputation of MADRS scores will be performed.) The distribution of delta MADRS scores in the population will be assessed for normality using visual analysis of histograms and using the Kolmogorov-Smirnoff test. If the delta MADRS scores are normally distributed, then the mean delta scores in the two groups will be compared using a two-sample t-test. If the delta MADRS scores are not normally distributed, then the median delta scores in the two groups will be compared using a Wilcoxon rank sum test.
  • Delta Sleep Ratio [ Time Frame: 2 days after intervention ]
    Electroencephalograms (EEG) will be captured using the Dreem headband (DREEM, Rhythm, New York, NY), a consumer-grade wireless device using dry electrodes. EEG will be captured overnight before surgery. Additional data collection using the Dreem headband will occur during the study medication infusion, the night following the study medication infusion, and the night following post-infusion day 1. The delta sleep ratio (DSR) will be defined as the ratio of slow wave activity (SWA = 1-4 Hz) during the first non-rapid eye movement (NREM) epoch to SWA during the second NREM epoch.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Official Title  ICMJE Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Brief Summary This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.
Detailed Description

This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial. Both the feasibility trial and the full-scale trial will follow a randomized, placebo-controlled, double-blinded, parallel design. The trial will follow a superiority design. This trial will take place at a single site (Washington University in St. Louis School of Medicine/Barnes-Jewish Hospital).

On the day following extubation, patients will be randomized to the intervention (ketamine group) or to control (control group). Patients in the ketamine group will receive a bolus of ketamine 0.5 mg/kg intravenously over 10 minutes, followed by an infusion at 0.3 mg/kg/h for an additional 7 hours 50 minutes. Patients in the control group will receive an equal volume of normal saline. Patients, research staff performing assessments, and research staff performing data analysis will be blinded to treatment allocation.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Postoperative Depression
Intervention  ICMJE
  • Drug: Ketamine
    NMDA antagonist
    Other Name: Ketalar
  • Drug: Normal saline
    IV fluid acting as a placebo
Study Arms  ICMJE
  • Experimental: Ketamine Arm
    On the first day following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 7 hours 50 minutes.
    Intervention: Drug: Ketamine
  • Placebo Comparator: Control Arm
    On the first day following surgery and extubation, patients will receive normal saline at an equal rate to that used in the ketamine arm.
    Intervention: Drug: Normal saline
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 3, 2022)
32
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2022
Estimated Primary Completion Date November 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Able to provide written, informed consent
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18 or older
  4. Scheduled for a surgery with planned intensive care unit admission at Barnes-Jewish Hospital
  5. Past medical history of depression, defined as one or more of the following criteria

    1. Previous diagnosis by a psychiatrist or primary care physician in an outpatient or inpatient setting, by patient report or chart documentation
    2. Prescription of an oral antidepressant by a psychiatrist or primary care physician for a mood disorder

Exclusion Criteria:

  1. Bipolar depression
  2. Outpatient antipsychotic medication use
  3. Emergent surgery
  4. Known or suspected elevation in intracranial pressure
  5. Subarachnoid hemorrhage
  6. Carotid endarterectomy or arteriovenous malformation repair
  7. Allergy to ketamine
  8. Any condition in which a significant elevation of blood pressure would constitute a serious hazard (e.g., aortic dissection, pheochromocytoma)
  9. Outpatient use of an anticonvulsant with significant sodium channel activity: carbamazepine, lacosamide, lamotrigine, oxcarbazepine, phenytoin, riluzole, and valproic acid
  10. Known history of dementia
  11. Pregnancy or lactation
  12. Inability to converse in English
  13. Concurrent enrollment in another interventional trial
  14. Postoperative mechanical ventilation continuing past 07:00am on postoperative day 3
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Bradley A Fritz, MD 314-273-3453 bafritz@wustl.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05233566
Other Study ID Numbers  ICMJE 202201107
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Bradley Fritz, Washington University School of Medicine
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Washington University School of Medicine
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Washington University School of Medicine
Verification Date April 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP